Logo

Galapagos Signs Huntington Disease Research Deal with High Q Foundation

Aug 12, 2005

NEW YORK, Aug. 12 (GenomeWeb News) - Galapagos said today that it has signed a two-year target-discovery agreement with the High Q Foundation, a non-profit organization that supports Huntington disease research.

 

High Q and Galadeno, Galapagos' partnering unit, will use Galapagos' adenoviral siRNA and cDNA collections to discover and validate drug targets for the development of new Huntington disease therapies.

 

Galapagos said that it could ultimately receive up to $3 million from the High Q Foundation for the project. The company also has the option to develop certain targets identified in the program.

 

Galapagos said that the final agreement with High Q has not yet been signed, but that it expects to do so before Oct. 1.

 

The company signed a similar agreement with the Cystic Fibrosis Foundation in April.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.